Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Immunologic Research
Erschienen in: Immunologic Research 1/2018

23.11.2017 | Review

T cell subsets: an integral component in pathogenesis of rheumatic heart disease

verfasst von: Devinder Toor, Neha Sharma

Erschienen in: Immunologic Research | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Acute rheumatic fever (ARF) is a consequence of pharyngeal infection of group A streptococcal (GAS) infection. Carditis is the most common manifestation of ARF which occurs in 30–45% of the susceptible individuals. Overlooked ARF cases might further progress towards rheumatic heart disease (RHD) in susceptible individuals, which ultimately leads to permanent heart valve damage. Molecular mimicry between streptococcal antigens and human proteins is the most widely accepted theory to describe the pathogenesis of RHD. In the recent past, various subsets of T cells have been reported to play an imperative role in the pathogenesis of RHD. Alterations in various T cell subsets, viz. Th1, Th2, Th17, and Treg cells, and their signature cytokines influence the immune responses and are associated with pathogenesis of RHD. Association of other T cell subsets (Th3, Th9, Th22, and TFH) is not defined in context of RHD. Several investigations have confirmed the up-regulation of adhesion molecules and thus infiltration of T cells into the heart tissues. T cells secrete both Th type 1 and type 2 cytokines and these auto-reactive T cells play a key role in progression of heart valve damage. In this review, we are going to discuss about the role of T cell subsets and their corresponding cytokines in the pathogenesis of RHD.
Literatur
1.
2.
Carapetis JR. The stark reality of rheumatic heart disease. Eur Heart J. 2015:12–5.
3.
Dajani AS, Ayoub E, Bierman FZ, Bisno AL, Denny FW, Durack DT, et al. Guidelines for the diagnosis of rheumatic fever: Jones criteria, updated 1992: special writing group of the committee on rheumatic fever, endocarditis, and Kawasaki disease of the council on cardiovascular disease in the young, American Heart Association. Circulation. 1993;87(1):302.
4.
Gewitz MH, Baltimore RS, Tani LY, Sable CA, Shulman ST, Carapetis J, et al. Revision of the Jones criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography a scientific statement from the American Heart Association. Circulation. 2015:1–14.
5.
Beaton A, Carapetis J. The 2015 revision of the Jones criteria for the diagnosis of acute rheumatic fever: implications for practice in low-income and middle-income countries. Heart Asia. 2015;7(2):7–11.PubMedPubMedCentralCrossRef
6.
Eroğlu AG. Update on diagnosis of acute rheumatic fever: 2015 Jones criteria. Türk Pediatr arşivi. 2016;51(1):1–7.
7.
Kumar D, Bhutia E, Kumar P, Shankar B, Juneja A, Chandelia S. Evaluation of American Heart Association 2015 revised Jones criteria versus existing guidelines. Heart Asia. 2016;8(1):30–5.PubMedPubMedCentralCrossRef
8.
Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. Lancet. 2012;379(9819):953–64.PubMedCrossRef
9.
Remenyi B, Wilson N, Steer A, Ferreira B, Kado J, Kumar K, et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease—an evidence-based guideline. Nat Rev Cardiol Nature Publishing Group. 2012;9(5):297–309.CrossRef
10.
Carapetis JR. Rheumatic heart disease in developing countries. N Engl J Med. 2007;357(5):439–41.PubMedCrossRef
11.
Zuhlke LJ, Steer AC. Estimates of the global burden of rheumatic heart disease. Glob Heart. 2013;8(3):189–95.PubMedCrossRef
12.
Guilherme L, Kalil J. Rheumatic fever: from sore throat to autoimmune heart lesions. Int Arch Allergy Immunol. 2004;134:56–64.PubMedCrossRef
13.
Kumar RK, Tandon R. Rheumatic fever & rheumatic heart disease: the last 50 years. Indian J Med Res. 2014:1–23.
14.
Guilherme L, Cury P, Demarchi LMF, Coelho V, Abel L, Lopez AP, et al. Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am J Pathol. 2004;165(5):1583–91.PubMedPubMedCentralCrossRef
15.
Guilherme L, Ramasawmy R, Kalil J. Rheumatic fever and rheumatic heart disease: genetics and pathogenesis. Scand J Immunol. 2007;66(2–3):199–207.PubMedCrossRef
16.
Guilherme L, Köhler KF, Postol E, Kalil J. Genes, autoimmunity and pathogenesis of rheumatic heart disease. Ann Pediatr Cardiol. 2011;4(1):13–21.PubMedPubMedCentralCrossRef
17.
Bijjiga E, Martino AT. Interleukin 10 (IL-10) regulatory cytokine and its clinical consequences. J Clin Cell Immunol. 2011:1–6.
18.
Ouyang W, Rutz S, Crellin N, Valdez P, Hymowitz S. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71–109.PubMedCrossRef
19.
Okello E, Kakande B, Sebatta E, Kayima J, Kuteesa M, Mutatina B, et al. Socioeconomic and environmental risk factors among rheumatic heart disease patients in Uganda. PLoS One. 2012;7(8):3–8.CrossRef
20.
Dobson J, Steer AC, Colquhoun S, Kado J. Environmental factors and rheumatic heart disease in Fiji. Pediatr Cardiol. 2012;33(2):332–6.PubMedCrossRef
21.
Riaz BK, Selim S, Karim N, Chowdhury KN, Chowdhury SH, Rahman R. Risk factors of rheumatic heart disease in Bangladesh: a case-control study. J Health Popul Nutr. 2013;31(1):70–7.PubMedPubMedCentralCrossRef
22.
Gray FG, Quinn RW, Quinn JP. A long-term survey of rheumatic and non-rheumatic families. Am J Med. 1952:1947–9.
23.
Wilson MG, Schweitzer M. Pattern of hereditary susceptibility in rheumatic fever. Circulation. 1954:699–705.
24.
Spanguolo M, Taranta A. Rheumatic fever in siblings—similarity of its clinical manifestations. N Engl J Med. 1968;278:183–8.CrossRef
25.
Ayoub EM, Barrett DJ, Maclaren NK, Krischer JP. Association of class II human histocompatibility leukocyte antigens with rheumatic fever. J Clin Invest. 1986;77:2019–26.PubMedPubMedCentralCrossRef
26.
Maharaj B, Khedun SM, Hammond MG, van der Byl K. HLA-A, B, DR, and DQ antigens in Indian patients with severe chronic rheumatic heart disease. Jpn Heart J. 1997;38(5):663–8.PubMedCrossRef
27.
Guedez Y, Kotby A, El-demellawy M, Galal A, Thomson G, Zaher S, et al. HLA class II associations with rheumatic heart disease. Circulation. 1999;99:2784–90.PubMedCrossRef
28.
Visentainer JE, Pereira FC, Dalalio MM, Tsuneto LT, Donadio PR, Moliterno RA. Association of HLA-DR7 with rheumatic fever in the Brazilian population. J Rheumatol. 2000;27(6):1518–20.PubMed
29.
Stanevicha V, Eglite J, Sochnevs A, Gardovska D, Zavadska D, Shantere R. HLA class II associations with rheumatic heart disease among clinically homogeneous patients in children in Latvia. Arthritis Res Ther. 2003;5(6):R340–6.PubMedPubMedCentralCrossRef
30.
Toor D, Leal K, Kumar R, Sharma YP, Chakraborti A. Association of HLA-DRB1*14 with rheumatic heart disease patients from Chandigarh. North India Biomarkers. 2012;17(2):160–5.PubMedCrossRef
31.
Jin Z, Ji Z, Hu J. Mannose-binding lectin gene site mutations and the susceptibility of rheumatic heart disease. Zhonghua Yi Xue Za Zhi China. 2001;81(21):1284–6.
32.
Ramasawmy R, Spina GS, Fae KC, Pereira AC, Nisihara R, Reason IJM, et al. Association of mannose-binding lectin gene polymorphism but not of mannose-binding serine protease 2 with chronic severe aortic regurgitation of rheumatic etiology. Clin Vaccine Immunol. 2008;15(6):932–6.PubMedPubMedCentralCrossRef
33.
Saraswathy R, Abilash VG, Manivannan G, George A, Babu KT. Four novel mutations detected in the exon 1 of MBL2 gene associated with rheumatic heart disease in South Indian patients. Int J Genet Mol Biol. 2010;2:165–70.
34.
Messias-Reason IJ, Schafranski MD, Kremsner PG, Kun JFJ. Ficolin 2 ( FCN 2 ) functional polymorphisms and the risk of rheumatic fever and rheumatic heart disease. Clin Exp Immunol. 2009;157:395–9.PubMedPubMedCentralCrossRef
35.
Catarino SJ, Boldt AB, Beltrame MH, Nisihara RM, Schafranski MD, de Messias-Reason IJ. Association of MASP2 polymorphisms and protein levels with rheumatic fever and rheumatic heart disease. Hum Immunol [Internet]. 2014;75(12):1197–202.CrossRef
36.
Settin A, Abdel-Hady H, El-Baz R, Saber I. Gene polymorphisms of TNF-alpha(-308), IL-10(-1082), IL-6(-174), and IL-1Ra(VNTR) related to susceptibility and severity of rheumatic heart disease. Pediatr Cardiol. 2007;28(5):363–71.PubMedCrossRef
37.
Guilherme L, Kalil J. Rheumatic heart disease: molecules involved in valve tissue inflammation leading to the autoimmune process and anti-S. pyogenes vaccine. Front Immunol. 2013;4:352.PubMedPubMedCentral
38.
Parks T, Mirabel MM, Kado J, Auckland K, Nowak J, Rautanen A, et al. Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania. Nat Commun. 2017;8:14946.PubMedPubMedCentralCrossRef
39.
Gray L, Antoine, HAD, Tong, SYC, Mckinnon M, Bessarab D, Brown N, et al. Genome-wide analysis of genetic risk factors for rheumatic heart disease in Aboriginal Australians provides support for pathogenic molecular mimicry. J Infect Dis. 2017.
40.
41.
Bisno AL, Read SE, Zabriskie JB. The concept of rheumatogenic and non-rheumatogenic group A streptococci, Streptococcal diseases and the immune response. New YorkAcademic Press; 1980;789–803.
42.
Shulman ST, Stollerman G, Beall B, Dale JB, Tanz RR. Temporal changes in streptococcal M protein types and the near-disappearance of acute rheumatic fever in the United States. Clin Infect Dis. 2006;42(4):441–7.PubMedCrossRef
43.
Krisher K, Cunningham MW. Myosin: a link between streptococci and heart. Science. 1985;227(4685):413–5.PubMedCrossRef
44.
Faé KC, da Silva DD, Oshiro SE, Tanaka AC, Pomerantzeff PM, Douay C, et al. Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease. J Immunol. 2006;176(9):5662–70.PubMedCrossRef
45.
Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med. 2003;9(7):914–20.PubMedCrossRef
46.
Kirvan CA, Cox CJ, Swedo SE, Cunningham MW. Tubulin is a neuronal target of autoantibodies in Sydenham’s chorea. J Immunol. 2007;178(11):7412–21.PubMedCrossRef
47.
Cox CJ, Sharma M, Leckman JF, Zuccolo J, Zuccolo A, Kovoor A, et al. Brain human monoclonal autoantibody from sydenham chorea targets dopaminergic neurons in transgenic mice and signals dopamine D2 receptor: implications in human disease. J Immunol. 2013;191(11):5524–41.PubMedCrossRef
48.
Kaplan MH. The concept of autoantibodies in rheumatic fever and in the postcommissurotomy state. Ann N Y Acad Sci. 1960;86:994–1.
49.
Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol. 1990;57(2):250–62.PubMedCrossRef
50.
Quinn A, Kosanke S, Fischetti VA, Factor SM, Cunningham MW. Induction of autoimmune valvular heart disease by recombinant streptococcal m protein. Infect Immun. 2001;69(6):4072–8.PubMedPubMedCentralCrossRef
51.
Li Y, Heuser JS, Kosanke SD, Hemric M, Cunningham MW. Cryptic epitope identified in rat and human cardiac myosin S2 region induces myocarditis in the Lewis rat. J Immunol. 2004;172(5):3225–34.PubMedCrossRef
52.
Rush CM, Govan BL, Sikder S, Williams NL, Ketheesan N. Animal models to investigate the pathogenesis of rheumatic heart disease. Front Pediatr. 2014;2:116.PubMedPubMedCentralCrossRef
53.
Galvin JE, Hemric ME, Ward K, Cunningham MW. Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin. J Clin Invest. 2000;106(2):217–24.PubMedPubMedCentralCrossRef
54.
Carapetis JR, Beaton A, Cunningham MW, Guilherme L, Karthikeyan G, Mayosi BM, et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Prim. 2016;15084
55.
Faé KC, Oshiro SE, Toubert A, Charron D, Kalil J, Guilherme L. How an autoimmune reaction triggered by molecular mimicry between streptococcal M protein and cardiac tissue proteins leads to heart lesions in rheumatic heart disease. J Autoimmun. 2005;24(2):101–9.PubMedCrossRef
56.
Toor D, Vohra H. Immune responsiveness during disease progression from acute rheumatic fever to chronic rheumatic heart disease. Microbes Infect. 2012;14(12):1111–7.PubMedCrossRef
57.
Itoh K, Hirohata S. The role of IL-10 in human B cell activation, proliferation, and differentiation. J Immunol. 1995;154(9):4341–50.PubMed
58.
Sharma N, Toor D. Interleukin-10: role in increasing susceptibility and pathogenesis of rheumatic fever/rheumatic heart disease. Cytokine. 2016;90:169–76.PubMedCrossRef
59.
Roberts S, Kosanke S, Dunn ST, Jankelow D, Duran CMG, Cunningham MW. Pathogenic mechanisms in rheumatic carditis: focus on valvular endothelium. J Infect Dis. 2001;183(3):507–11.PubMedCrossRef
60.
Tandon R, Sharma M, Chandrashekhar Y, Kotb M, Yacoub MH, Narula J. Revisiting the pathogenesis of rheumatic fever and carditis. Nat Rev Cardiol. 2013;10(3):171–7.PubMedCrossRef
61.
Cunningham MW. Rheumatic fever, autoimmunity and molecular mimicry: the streptococcal connection. Int Rev Immunol. 2014;33:314–29.
62.
Root-bernstein R. Rethinking molecular mimicry in rheumatic heart disease and autoimmune myocarditis: laminin, collagen IV, CAR, and B1AR as initial targets of disease. Front Pediatr. 2014;2(August):1–17.
63.
Dinkla K, Rohde M, Jansen WTM, Kaplan EL, Chhatwal GS, Talay SR. Rheumatic fever-associated Streptococcus pyogenes isolates aggregate collagen. J Clin Invest. 2003 Jun;111(12):1905–12.PubMedPubMedCentralCrossRef
64.
Dinkla K, Nitsche-Schmitz DP, Barroso V, Reissmann S, Johansson HM, Frick I-M, et al. Identification of a streptococcal octapeptide motif involved in acute rheumatic fever. J Biol Chem. 2007;282(26):18686–93.PubMedCrossRef
65.
Dinkla K, Talay SR, Morgelin M, Graham RMA, Rohde M, Nitsche-Schmitz DP, et al. Crucial role of the CB3-region of collagen IV in PARF-induced acute rheumatic fever. PLoS One. 2009;4(3):e4666.PubMedPubMedCentralCrossRef
66.
Chhatwal GS. Host-pathogen interactions in streptococcal diseases [Internet]. Springer Berlin Heidelberg; 2014. (Current Topics in Microbiology and Immunology).
67.
De Oliveira Martins C, Demarchi L, Ferreira FM, Pomerantzeff PMA, Brandao C, Sampaio RO, et al. Rheumatic heart disease and myxomatous degeneration: differences and similarities of valve damage resulting from autoimmune reactions and matrix disorganization. PLoS One. 2017;12(1):1–12.
68.
Guilherme L, Köhler KF, Kalil J. Rheumatic heart disease. Mediation by complex immune events. Adv Clin Chem. 2011;53(C):31–50.PubMedCrossRef
69.
Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol. 1993;11:729–66.PubMedCrossRef
70.
Lehmann P V, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen 1992;358(6382):155–157.
71.
Ellis NMJ, Li Y, Hildebrand W, Fischetti VA, Cunningham MW. T cell mimicry and epitope specificity of cross-reactive T cell clones from rheumatic heart disease. J Immunol. 2005;175(8):5448–56.PubMedCrossRef
72.
Guilherme L, Kalil J. Role of autoimmunity in rheumatic fever. Fut Rheumatol Future Medicine. 2008;3(2):161–7.CrossRef
73.
Guilherme L, Kalil J. Rheumatic fever and rheumatic heart disease: cellular mechanisms leading autoimmune reactivity and disease. J Clin Immunol. 2009;30(1):17–23.PubMedCrossRef
74.
Guilherme L, Dulphy N, Douay C, Coelho V, Cunha-Neto E, Oshiro SE, et al. Molecular evidence for antigen-driven immune responses in cardiac lesions of rheumatic heart disease patients. Int Immunol. 2000;12(7):1063–74.PubMedCrossRef
75.
Cunningham MW. Autoimmunity and molecular mimicry in the pathogenesis of post-streptococcal heart disease. Front Biosci. 2003;8:s533–43.PubMedCrossRef
76.
Guilherme L, Kalil J, Cunningham M. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. Autoimmunity. 2006;39(1):31–9.
77.
Martin WJ, Steer AC, Smeesters PR, Keeble J, Inouye M, Carapetis J, et al. Post-infectious group A streptococcal autoimmune syndromes and the heart. Autoimmun Rev. 2015;14(8):710–25.PubMedCrossRef
78.
Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C. Animal models. Ann Neurol. 1994;36:S47–53.PubMedCrossRef
79.
Brimberg L, Benhar I, Mascaro-Blanco A, Alvarez K, Lotan D, Winter C, et al. Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology. 2012;37(9):2076–87.PubMedPubMedCentralCrossRef
80.
Kaplan MH. Rheumatic fever, rheumatic heart disease, and the streptococcal connection: the role of streptococcal antigens cross-reactive with heart tissue. Rev Infect Dis. 1979;1(6):986–8.CrossRef
81.
Zabriskie JB. Rheumatic fever: a streptococcal-induced autoimmune disease? Pediatr Ann. 1982;11(4):383–96.PubMedCrossRef
82.
Senitzer D, Freimer EH. Autoimmune mechanisms in the pathogenesis of rheumatic fever. Rev Infect Dis. 1984;6
83.
Stollerman GH. Rheumatogenic streptococci and autoimmunity. Clin Immunol Immunopathol. 1991;61(2 Pt 1):131–42.PubMedCrossRef
84.
Williams RC, Prakash K, Van de Rijn I, Zabriskie JB. Changes in T-lymphocyte subsets during acute rheumatic fever. J Clin Immunol. 1982;2(3):166–72.PubMedCrossRef
85.
Raizada V, Williams RC, Chopra P, Gopinath N, Prakash K, Sharma KB, et al. Tissue distribution of lymphocytes in rheumatic heart valves as defined by monoclonal anti-T cell antibodies. Am J Med. 1983;74(1):90–6.PubMedCrossRef
86.
Kemeny E, Grieve T, Marcus R, Sareli P, Zabriskie JB. Identification of mononuclear cells and T cell subsets in rheumatic valvulitis. Clin Immunol Immunopathol. 1989;52(2):225–37.PubMedCrossRef
87.
Reddy KS, Narula J, Bhatia R, Shailendri K, Koicha M, Taneja V, et al. Immunologic and immunogenetic studies in rheumatic fever and rheumatic heart disease. Indian J Pediatr. 1990;57(5):693–700.PubMedCrossRef
88.
Morris K, Mohan C, Wahi PL, Anand IS, Ganguly NK. Increase in activated T cells and reduction in suppressor/cytotoxic T cells in acute rheumatic fever and active rheumatic heart disease: a longitudinal study. J Infect Dis. 1993;167(4):979–83.PubMedCrossRef
89.
Guilherme L, Cunha-Neto E, Coelho V, Snitcowsky R, Pomerantzeff PMA, Assis RV, et al. Human heart–infiltrating T-cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. Circulation. 1995;92:415–20.PubMedCrossRef
90.
Bhatnagar A, Grover A, Ganguly NK. Superantigen-induced T cell responses in acute rheumatic fever and chronic: rheumatic heart disease patients. Clin Exp Immunol. 1999;116(1):100–6.PubMedPubMedCentralCrossRef
91.
Kirvan CA, Galvin JE, Hilt S, Kosanke S, Cunningham MW. Identification of streptococcal M-protein cardiopathogenic epitopes in experimental autoimmune valvulitis. J Cardiovasc Transl Res. 2014;7(2):172–81.PubMedCrossRef
92.
Gorton D, Sikder S, Williams NL, Chilton L, Rush CM, Govan BL, et al. Repeat exposure to group A streptococcal M protein exacerbates cardiac damage in a rat model of rheumatic heart disease. Autoimmunity. 2016;49(8):563–70.PubMedPubMedCentralCrossRef
93.
94.
Miller LC, Gray ED, Mansour M, Abdin ZH, Kamel R, Zaher S, et al. Cytokines and immunoglobulin in rheumatic heart disease: production by blood and tonsillar mononuclear cells. J Rheumatol. 1989;16(11):1436–42.PubMed
95.
Lane JR, Neumann DA, Lafond-walker A, Herskowitz A, Rose NR. Interleukin 1 or tumor necrosis factor can promote Coxsackie B3-induced myocarditis in resistant B10.A mice. J Exp Med. 1992;175:1123–9.PubMedCrossRef
96.
Yeǧin O, Coşkun M, Ertuǧ H. Cytokines in acute rheumatic fever. Eur J Pediatr. 1997;156(1):25–9.PubMedCrossRef
97.
Fraser WJ, Haffejee Z, Jankelow D, Wadee A, Cooper K. Rheumatic Aschoff nodules revisited. II: cytokine expression corroborates recently proposed sequential stages. Histopathology. 1997;31(5):460–4.PubMedCrossRef
98.
Hafez M, EL-Morsy Z, EL-Shennawy F, Hawas S, Sheishaa A, Abo-EL-Kheir M, et al. Susceptibility to over production of cytokines in acute rheumatic carditis and their role in the pathogenesis. J Med Sci. 2002;2(2):65–73.CrossRef
99.
Mills KHG, Dunne A. Immune modulation: IL-1, master mediator or initiator of inflammation. Nat Med. 2009;15(12):1363–4.PubMedCrossRef
100.
101.
Schiff MH. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis [Internet]. 2000;59:i103–8.CrossRef
102.
Azevedo PM, Bauer R, Vde Caparbo F, Silva CAA, Bonfa E, Pereira RMR. Interleukin-1 receptor antagonist gene (IL1RN) polymorphism possibly associated to severity of rheumatic carditis in a Brazilian cohort. Cytokine. 2010;49(1):109–13.PubMedCrossRef
103.
Chou H-T, Tsai C-H, Chen W-C, Tsai F-J. Lack of association of genetic polymorphisms in the interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 genes with risk of rheumatic heart disease in Taiwan Chinese. Int Heart J. 2005;46(3):397–406.PubMedCrossRef
104.
Zheng L, Sharma R, Gaskin F, Fu SM, Ju S-T. A novel role of IL-2 in organ-specific autoimmune inflammation beyond regulatory T cell checkpoint: both IL-2 knockout and Fas mutation prolong lifespan of Scurfy mice but by different mechanisms. J Immunol. 2007;179(12):8035–41.PubMedPubMedCentralCrossRef
105.
Sharma R, Sharma PR, Kim Y, Leitinger N, Lee JK, Fu SM, et al. IL-2–controlled expression of multiple T cell trafficking genes and Th2 cytokines in the regulatory T cell-deficient scurfy mice: implication to multiorgan inflammation and control of skin and lung inflammation. J Immunol. 2011;186(2):1268–78.PubMedCrossRef
106.
107.
Moon BI, Kim TH, Seoh JY. Functional modulation of regulatory T cells by IL-2. PLoS One. 2015;10(11):1–13.CrossRef
108.
Zedan MM, El-Shennawy FA, Abou-Bakr HM, Al-Basousy AM. Interleukin-2 in relation to T cell subpopulations in rheumatic heart disease. Arch Dis Child. 1992;67(11):1373–5.PubMedPubMedCentralCrossRef
109.
Narin N, Kutukculer N, Ozyurek R, Bakiler AR, Parlar A, Arcasoy M. Lymphocyte subsets and plasma IL-1 alpha, IL-2, and TNF-alpha concentrations in acute rheumatic fever and chronic rheumatic heart disease. Clin Immunol Immunopathol. 1995;77(2):172–6.PubMedCrossRef
110.
Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201(5):723–35.PubMedPubMedCentralCrossRef
111.
Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006;108(5):1571–9.PubMedPubMedCentralCrossRef
112.
Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol. 2007;178(4):2018–27.PubMedCrossRef
113.
Mukhopadhyay S, Varma S, Gade S, Yusuf J, Trehan V, Tyagi S. Regulatory T-cell deficiency in rheumatic heart disease: a preliminary observational study. J Heart Valve Dis. 2013;22(1):118–25.PubMed
114.
Mukhopadhyay S, Varma S, Mohan Kumar HN, Yusaf J, Goyal M, Mehta V, et al. Circulating level of regulatory T cells in rheumatic heart disease: an observational study. Indian Heart J. 2016;68(3):342–8.PubMedPubMedCentralCrossRef
115.
Mohamed AA, Rashed LA, Shaker SM, Ammar RI. Association of tumor necrosis factor-alpha polymorphisms with susceptibility and clinical outcomes of rheumatic heart disease. Saudi Med J. 2010;31(6):644–9.PubMed
116.
Sedgwick JD, Riminton DS, Cyster JG, Korner H. Tumor necrosis factor: a master-regulator of leukocyte movement. Immunol Today. 2000;21(3):110–3.PubMedCrossRef
117.
Campbell IL, Oxbrow L, Koulmanda M, Harrison LC. IFN-gamma induces islet cell MHC antigens and enhances autoimmune, streptozotocin-induced diabetes in the mouse. J Immunol. 1988;140(4):1111–6.PubMed
118.
Benzabya W. Interleukin 8 and tumor necrosis factor- α level in acute rheumatic fever and chronic rheumatic heart disease. Libyan J Med Res. 2014;8(1):4–7.
119.
Arya DK, Sharma A, Mehta G, Dua M, Johri AK. Molecular epidemiology and virulence characteristics of prevalent group A streptococci recovered from patients in northern India. J Infect Dev Ctries. 2014;8(3):271–81.PubMedCrossRef
120.
Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002;13(4–5):357–68.PubMedCrossRef
121.
122.
123.
Md Yusof MY, Emery P. Targeting interleukin-6 in rheumatoid arthritis. Drugs. 2013;73(4):341–56.PubMedCrossRef
124.
Dienz O, Eaton SM, Bond JP, Neveu W, Moquin D, Noubade R, et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med. 2009;206(1):69–78.PubMedPubMedCentralCrossRef
125.
Azevedo PM, Merriman TR, Topless RK, Wilson NJ, Crengle S, Lennon DR. Association study involving polymorphisms in IL-6, IL-1RA, and CTLA4 genes and rheumatic heart disease in New Zealand population of Maori and Pacific ancestry. Cytokine. 2016;85:201–6.PubMedCrossRef
126.
Endo H, Akahoshi T, Takagishi K, Kashiwazaki S, Matsushima K. Elevation of interleukin-8 (IL-8) levels in joint fluids of patients with rheumatoid arthritis and the induction by IL-8 of leukocyte infiltration and synovitis in rabbit joints. Lymphokine Cytokine Res. 1991;10(4):245–52.PubMed
127.
Berger A. Th1 and Th2 responses: what are they? BMJ. 2000;321(7258):424.
128.
Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009;21(12):1303.PubMedCrossRef
129.
Leão SC, Lima MR, Nascimento HM, Octacilio-Silva S, TM R. IL-10 and ET-1 as biomarkers of rheumatic valve disease. Rev Bras Cir Cardiovasc. 2014;29(1):25–30.PubMedPubMedCentralCrossRef
130.
Koppelman B, Neefjes JJ, De Vries JE. Interleukin-10 down-regulates MHC class II αβ peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity. 1997;7:861–71.PubMedCrossRef
131.
132.
Llorente BL, Zou W, Levy Y, Richaud-patin Y, Wijdenes J, Alcocer-varela IIJ, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic luppus erythematosus. J Exp Med. 1995;181:839–44.PubMedCrossRef
133.
Ravirajan CT, Wang Y, Matis LA, Papadaki L, Griffiths MH, Latchman DS, et al. Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody. Rheumatology. 2004;43(4):442–7.PubMedCrossRef
134.
Rahim SS, Khan N, Boddupalli CS, Hasnain SE, Mukhopadhyay S. Interleukin-10 (IL-10) mediated suppression of IL-12 production in RAW 264.7 cells involves c-rel transcription factor. Immunology. 2005;114:313–21.PubMedPubMedCentralCrossRef
135.
D’Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med. 1993;178(3):1041–8.PubMedCrossRef
136.
Ito S, Ansari P, Sakatsume M, Dickensheets H, Vazquez N, Donnelly RP, et al. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood. 1999;93(5):1456–63.PubMed
137.
Kim L, Kim DK, Yang WI, Shin DH, Jung IM, Park HK, et al. Overexpression of transforming growth factor-beta 1 in the valvular fibrosis of chronic rheumatic heart disease. J Korean Med Sci. 2008;23(1):41–8.PubMedPubMedCentralCrossRef
138.
Xiao H, Lei H, Qin S, Ma K, Wang X. TGF-beta1 expression and atrial myocardium fibrosis increase in atrial fibrillation secondary to rheumatic heart disease. Clin Cardiol. 2010;33(3):149–56.PubMedCrossRef
139.
El-Din SS, Senna WGA. The role of transforming growth factor beta 1 in rheumatic mitral valve disease. Histological and immunohistochemical study. J Egypt Soc Cardio-Thoracic Surg. 2011;19:45–51.
140.
Bujak M, Frangogiannis NG. The role of TGF-β signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007;74:184–95.PubMedCrossRef
141.
Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51:600–6.
142.
Frangogiannis NG. The role of transforming growth factor (TGF)-β in the infarcted myocardium. J Thorac Dis. 2017;9:S52–63.
143.
Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485–517.PubMedCrossRef
144.
Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang Y-H, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133–41.PubMedPubMedCentralCrossRef
145.
Wen Y, Zeng Z, Gui C, Li L, Li W. Changes in the expression of Th17 cell-associated cytokines in the development of rheumatic heart disease. Cardiovasc Pathol. 2015;24(6):382–7.PubMedCrossRef
146.
Dileepan T, Linehan JL, Moon JJ, Pepper M, Jenkins MK, Cleary PP. Robust antigen specific th17 t cell response to group a streptococcus is dependent on il-6 and intranasal route of infection. PLoS Pathog. 2011;7(9):e1002252.PubMedPubMedCentralCrossRef
147.
Qin H, Wang L, Feng T, Elson CO, Niyongere SA, Lee SJ, et al. TGF-β promotes Th17 cell development through inhibition of SOCS3. J Immunol. 2009;183:97–105.PubMedPubMedCentralCrossRef
148.
149.
Wynn TA. Mechanism of fibrosis: therapeutic transplation for fibrotic disease. Nat Med. 2013;18(7):1028–40.CrossRef
150.
Borthwick LA, Wynn TA, Fisher AJ. Cytokine mediated tissue fibrosis. Biochim Biophys Acta - Mol Basis Dis. 2013;1832(7):1049–60.CrossRef
151.
Mi S, Li Z, Yang H-Z, Liu H, Wang J-P, Ma Y-G, et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol. 2011;187(6):3003–14.PubMedCrossRef
152.
Bas HD, Baser K, Yavuz E, Bolayir HA, Yaman B, Unlu S, et al. A shift in the balance of regulatory T and T helper 17 cells in rheumatic heart disease. J Investig Med. 2014;62(1):78–83.PubMedCrossRef
153.
Chong DLW, Ingram RJ, Lowther DE, Muir R, Sriskandan S, Altmann DM. The nature of innate and adaptive interleukin-17A responses in sham or bacterial inoculation. Immunology. 2012;136(3):325–33.PubMedPubMedCentralCrossRef
154.
Bryant PA, Smyth GK, Gooding T, Oshlack A, Harrington Z, Currie B, et al. Susceptibility to acute rheumatic fever based on differential expression of genes involved in cytotoxicity, chemotaxis, and apoptosis. Infect Immun. 2014;82(2):753–61.PubMedPubMedCentralCrossRef
155.
Dileepan T, Smith ED, Knowland D, Hsu M, Platt M, Bittner-Eddy P, et al. Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th17 cells. J Clin Invest. 2016;126(1):303–17.PubMedCrossRef
156.
Huppert J, Closhen D, Croxford A, White R, Kulig P, Pietrowski E, et al. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J Off Publ Fed Am Soc Exp Biol. 2010;24(4):1023–34.
157.
Wang B, Dileepan T, Briscoe S, Hyland KA, Kang J, Khoruts A, et al. Induction of TGF- 1 and TGF- 1-dependent predominant Th17 differentiation by group A streptococcal infection. Proc Natl Acad Sci. 2010;107(13):5937–42.PubMedPubMedCentralCrossRef
158.
Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediat Inflamm. 2017;2017:1–11.CrossRef
159.
Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci. 2012;122(11):487–511.PubMedCrossRef
160.
Zambrano-Zaragoza JF, Romo-Martínez EJ, Durán-Avelar MDJ, García-Magallanes N, Vibanco-Pérez N. Th17 cells in autoimmune and infectious diseases. Int J Inflam. 2014;2014(Il).
161.
Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K. The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp. 2015;63(6):435–49.CrossRef
162.
Grant CR, Liberal R, Mieli-Vergani G, Vergani D, Longhi MS. Regulatory T-cells in autoimmune diseases: challenges, controversies and—yet—unanswered questions. Autoimmun Rev. 2015;14(2):105–16.PubMedCrossRef
163.
Abdul-Auhaimena N, Al-Kaabi ZIL. Functional and developmental analysis of CD4(+)CD25(+) regulatory T cells under the influence of streptococcal M protein in rheumatic heart disease. Iran J Med Sci. 2011;36:122–7.PubMedPubMedCentral
164.
Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4(+)CD25(hi) T-regulatory cells. Blood. 2006;108:253–61.PubMedPubMedCentralCrossRef
165.
Fujimoto M, Nakano M, Terabe F, Kawahata H, Ohkawara T, Han Y, et al. The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J Immunol. 2011;186(1):32–40.PubMedCrossRef
166.
Lin G, Wang J, Lao X, Wang J, Li L, Li S, et al. Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells. J Immunother. 2012;35(4):337–43.PubMedCrossRef
167.
Dale JB, Beachey EH. Human cytotoxic T lymphocytes evoked by group A streptococcal M proteins. J Exp Med. 1987;166(6):1825–35.PubMedCrossRef
168.
Ganguly NK, Anand IS, Khanna AK, Kohli RS, Wahi PL. T cells and T cell subsets in rheumatic heart disease. Indian J Med Res. 1982;76:854–8.PubMed
169.
Lue HC, Tseng WP, Lin GJ, Hsieh KH, Hsieh RP, Chiou JF. Clinical and epidemiological features of rheumatic fever and rheumatic heart disease in Taiwan and the Far East. Indian Heart J India. 1983;35(3):139–46.
170.
Jinquan T, Larsen CG, Gesser B, Matsushima K, Thestrup-Pedersen K. Human IL-10 is a chemoattractant for CD8+ T lymphocytes and an inhibitor of IL-8-induced CD4+ T lymphocyte migration. J Immunol. 1993;151(9):4545–51.PubMed
171.
Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Roman JJ, et al. Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8 ϩ cytotoxic T lymphocytes. J Virol. 2000;74(10):4729–37.PubMedPubMedCentralCrossRef
172.
Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol. 1998;160(7):3188–93.PubMed
173.
Rowbottom AW, Lepper MW, Garland RJ, Cox CV, Corley EG, Oakhill A, et al. Interleukin-10-induced CD8 cell proliferation. Immunology. 1999;98:80–9.PubMedPubMedCentralCrossRef
174.
MacNeil IA, Suda T, Moore KW, Mosmann TR, Zlotnik A. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol. 1990;145(12):4167–73.PubMed
175.
176.
Wong MT, Ye JJ, Alonso MN, Landrigan A, Cheung RK, Engleman E, et al. Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol Cell Biol. 2010;88(6):624–31.PubMedPubMedCentralCrossRef
177.
Singh TP, Schön MP, Wallbrecht K, Gruber-Wackernagel A, Wang XJ, Wolf P. Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. PLoS One. 2013;8(1):1–11.
178.
Hughes-austin JM, Deane KD, Derber LA, Kolfenbach JR, Gary O, Sokolove J, et al. Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: studies of the aetiology of rheumatoid arthritis (SERA). Ann Rheum Dis. 2013;72(6):901–7.PubMedCrossRef
179.
Deng Y, Wang Z, Chang C, Lu L, Lau CS, Lu Q. Th9 cells and IL-9 in autoimmune disorders: pathogenesis and therapeutic potentials. Hum Immunol. 2017;78(2):120–8.PubMedCrossRef
180.
Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J, et al. Transforming growth factor-beta “reprograms” the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol. 2008;9(12):1341–6.PubMedCrossRef
181.
Li Y, Yu Q, Zhang Z, Wang J, Li S, Zhang J, et al. T(H)9 cell differentiation, transcriptional control and function in inflammation, autoimmune diseases and cancer. Oncotarget. 2016;7:71001–12.PubMedPubMedCentral
182.
Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi A, Imitola J, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci. 2009;106(31):12885–90.PubMedPubMedCentralCrossRef
183.
184.
Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev. 2013;252(1):116–32.PubMedCrossRef
185.
186.
Cho KA, Suh JW, Ho Lee K, Kang JL, Woo SY. IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of il-1β by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int Immunol. 2012;24(3):147–58.PubMedCrossRef
187.
Sabat R, Witte E, Witte K, Wolk K. IL-17, IL-22 and their producing cells: role in inflammation and autoimmunity. Prog Inflamm Res 2013;11–36.
188.
Sugita S, Kawazoe Y, Imai A, Kawaguchi T, Horie S, Keino H, et al. Role of IL-22- and TNF-alpha-producing Th22 cells in uveitis patients with Behcet’s disease. J Immunol. 2013;190(11):5799–808.PubMedPubMedCentralCrossRef
189.
Azizi G, Yazdani R, Mirshafiey A. Th22 cells in autoimmunity: a review of current knowledge. Eur Ann Allergy Clin Immunol. 2015;47(4):108–17.PubMed
190.
Weiner HL. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect. 2001;3(11):947–54.PubMedCrossRef
191.
Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994;265(5176):1237–40.PubMedCrossRef
192.
Peterson RA. Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression. Toxicol Pathol. 2012;40(2):186–204.PubMedCrossRef
193.
Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol. 2003;171(12):6323–7.PubMedCrossRef
194.
Gol-Ara M, Jadidi-Niaragh F, Sadria R, Azizi G, Mirshafiey A. The role of different subsets of regulatory T cells in immunopathogenesis of rheumatoid arthritis. Arthritis. 2012;2012:805875.PubMedPubMedCentralCrossRef
195.
Chou H-T, Chen C-H, Tsai C-H, Tsai F-J. Association between transforming growth factor-beta1 gene C-509T and T869C polymorphisms and rheumatic heart disease. Am Heart J. 2004 Jul;148(1):181–6.PubMedCrossRef
196.
197.
198.
Metadaten
Titel
T cell subsets: an integral component in pathogenesis of rheumatic heart disease
verfasst von
Devinder Toor
Neha Sharma
Publikationsdatum
23.11.2017
Verlag
Springer US
Erschienen in
Immunologic Research / Ausgabe 1/2018
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-017-8978-z

Weitere Artikel der Ausgabe 1/2018

Immunologic Research 1/2018 Zur Ausgabe

Original Article

Screening HCV genotype-specific epitope peptides based on conserved sequence analysis and B cell epitope prediction in HCV E2 region

Original Article

CD28neg. T lymphocytes of a melanoma patient harbor tumor immunity and a high frequency of germline-encoded and public TCRs

Original Article

Long-term presence of angiotensin II type 1 receptor autoantibody reduces aldosterone production by triggering Ca2+ overload in H295R cells

Original Article

Th2-biased immune response and agglutinating antibodies generation by a chimeric protein comprising OmpC epitope (323–336) of Aeromonas hydrophila and LTB

Original Article

Cellular immune response in MDR-TB patients to different protein expression of MDR and susceptible Mycobacterium tuberculosis: Rv0147, a novel MDR-TB biomarker

Original Article

Polymorphisms in inflammation-related genes and the risk of primary varicose veins in ethnic Russians

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?

16.04.2024 | Tonsillektomie | Nachrichten

Intrakapsuläre Tonsillektomie gewinnt an Boden

15.04.2024 | Hörsturz | Nachrichten

Bilateraler Hörsturz hat eine schlechte Prognose

08.04.2024 | Larynxpapillomatose | Nachrichten

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert
weitere anzeigen

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen